Loading...
•
Mar 31, 2022
Praxis Q1 2022 Earnings Report
Praxis reported financial results for the first quarter 2022 and provided a corporate update.
Key Takeaways
Praxis Precision Medicines reported a net loss of $68.7 million for the first quarter of 2022. As of March 31, 2022, the company's cash, cash equivalents, and marketable securities totaled $222.5 million, expected to fund operations into the third quarter of 2023.
PRAX-944 demonstrated clinically meaningful functional improvement in essential tremor patients in Part B of Phase 2a study
PRAX-114 Phase 2/3 monotherapy MDD Aria Study completed; topline results expected in June 2022
Epilepsy Day showcases largest targeted epilepsy portfolio in industry
Cash and investments of $222.5 million as of March 31, 2022 supports runway into 3Q23
Forward Guidance
Praxis Precision Medicines expects cash, cash equivalents and marketable securities as of March 31, 2022 are expected to fund operations into the third quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...